Clinical significance of tumor markers and an emerging perspective on colorectal cancer

Cancer Science

Volumn 100, Issue 2, 2009, Pages 195-199

  Yamashita, Keishi ^a   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ANAPHYLATOXIN; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CALGRANULIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLIC ACID; K RAS PROTEIN; OXALIPLATIN; PENITUMUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BLOOD ANALYSIS; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FECES ANALYSIS; HUMAN; MICROSATELLITE MARKER; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; VALIDATION PROCESS;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58549090341     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01022.x     Document Type: Review

References (41)

1. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-71.
2. Mandel JS, Church TR, Ederer F et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-7.
3. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with fecal-occult-blood test. Lancet 1996; 348: 1467-71.
4. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of fecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
5. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133: 573-84.
6. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5.
7. Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
8. Gorg A, Obermaier C, Boguth G et al. Very alkaline immobilized pH gradients for two-dimensional electrophoresis of ribosomal and nuclear proteins. Electrophoresis 1997; 18: 328-37.
9. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-7.
10. Veenstra TD, Prieto DA, Conrads TP. Proteomic patterns for early cancer detection. Drug Dicov Today 2004; 9: 889-97.
11. Conrads TP, Hood BL, Issaq HJ et al. Proteomic patterns as a diagnostic tool for early-stage cancer: A review of its progress to a clinically relevant tool. Mol Design 2004; 8: 77-85.
12. Locker GY, Hamilton S, Harris J et al. ASCO: Update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
13. Wanebo HJ, Rao B, Pinsky CM. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 448-51.
14. Scott NA, Wieand HS, Moertel CG. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987; 122: 1375-9.
15. Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988; 31: 33-41.
16. Harrison LE, Guillem JG, Paty P et al. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: A multivariate analysis of 572 patients. J Am Coll Surg 1997; 185: 55-9.
17. Marchena J, Acosta MA, Garcia-Anguiano F. Use of the preoperative levels of CEA in patients with colorectal cancer. Hepatogastroenterology 2003; 50: 1017-20.
18. Weissenberger C, Von Plehn G, Otto F. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: Role of CEA and CA 19-9. Anticancer Res 2005; 25: 1787-93.
19. Chen CC, Yang SH, Lin JK. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 2005; 124: 169-74.
20. Katoh H, Yamashita K, Satoh T et al. Validation of prognostic impact of preoperative carcinoembryonic antigen (CEA) in Dukes'C colorectal cancer. A prospective study. Anticancer Res 2008; 28 (3B): 1933-41.
21. Katoh H, Yamashita K, Kokuba Y et al. Surgical resection of stage IV colorectal cancer and prognosis. World J Surg 2008; 32: 1130-7.
22. Wang WS, Lin JK, Chiou TJ. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepato-Gastroenterology 2002; 49: 160-4.
23. Trillet-Lenoir VCF, Touzet S, Barbier JY et al. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) 2004; 16: 196-203.
24. Roseth AG, Kristinsson J, Fagerhol MK. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993; 28: 1073-6.
25. Traverso G, Shuber A, Levin B. Detection of APC mutation in fecal DNA from patients with colorectal cancer. N Engl J Med 2002; 346: 311-20.
26. Yu JK, Chen YD, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol 2004; 10: 3127-31.
27. Melle C, Ernst G, Schimmel B. Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005; 129: 66-73.
28. Habermann JK, Roblick UJ, Luke BT. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006; 131: 1020-9.
29. Hiramatsu KTK, Yamaguchi T, Matsumoto H et al. N(1), N(12)-Diacetylspermineas a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res 2005; 11: 2986-90.
30. Nori D, Merimsky O, Samala E et al. Tumor ploidy as a risk factor for disease recurrence oand short survival in surgically-treated Dukes B2 colon cancer. J Surg Oncol 1995; 59: 239-42.
31. Lanza G, Gafa R, Santini A et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: A prospective flow cytometric study. Cancer 1998; 82: 49-59.
32. Araujo SE, Bernardo WM, Habr-Gama A et al. DNA ploidy status andprognosis in colorectal cancer: A meta-analysis of published data. Dis Colon Rectum 2007; 50: 1800-10.
33. Zhou W, Goodman SN, Galizia G et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002; 359: 219-25.
34. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22: 1564-71.
35. Ribic CM, Sargent DJ, Moore MJ. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy. N Engl J Med 2003; 349: 247-57.
36. Branch P, Aquilina G, Bignami M et al. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993; 362: 652-4.
37. Andreyev HJNA, Cunningham D, Oates J et al. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001; 85: 692-6.
38. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter 'RASCAL' study. J Natl Cancer Inst 1998; 90: 675-84.
39. Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and lecovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
40. Khambata-Ford SGC, Meropol NJ, Basik M et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
41. Benvenuti SS-BA, Di Nicolantonio F, Zanon C et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-8.